IMIBD Section: Defining State-of-the-Art Care in IBD
April 17, 2017
The Immunology, Microbiology & Inflammatory Bowel Diseases section highlights must-see sessions at DDW® 2017 that showcase exciting and innovative research.
Mark S. Silverberg, MD, PhD (chair), and Uma Mahadevan, MD, AGAF (vice chair), of the Immunology, Microbiology & Inflammatory Bowel Diseases section are excited to share their top three must-see sessions at Digstive Disease Week® (DDW) 2017.
View the AGA Institute Council Highlights at DDW 2017 booklet to learn about all section programming, committee sponsored and joint society sessions, as well as a plethora of basic science and clinical practitioner offerings.
Session Title: The Pregnant Patient with IBD: Data for an International Consensus?!
Session Date: Sunday, May 7, 2017
Session Time: 2 p.m.
Why You Should Attend: This is an exciting and interactive new format for DDW. There will be five research abstract presentations that update where we are in the management of pregnant patients with IBD. The sixth presentation will be a discussion among attendees and IBD experts on what consensus we can reach internationally on management of this complex patient population, particularly with respect to continuing biologics and immunomodulators throughout pregnancy.
Session Title: Immunology, Microbiology and IBD Distinguished Abstract Plenary and Section Business Meeting
Session Date: Monday, May 8, 2017
Session Time: 4 p.m.
Why You Should Attend: This is the best of the best clinical and basic science IBD abstracts for 2017. Of 970 abstracts submitted to IMIBD, come hear the six best!
Session Title: Farron and Martin Brotman, MD, Lecture — The Modern Medical Management of IBD: Biologics, Biosimilars and Small Molecules
Session Date: Tuesday, May 9, 2017
Session Time: 8 a.m.
Why You Should Attend: If you are going to attend only one session in IBD, this is the one for you. It will feature a concise update on biologics, biosimilars and small molecules so you are up-to-date on the very latest arsenal for the treatment of IBD.